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Fig. A, Venous ulcer. B, Healed ulcer after applications of human
viable wound matrix (HVWM). C, Healing rates versus compression alone.
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Volume 60, Number 3 Abstracts 829plus deep system, reﬂux in all patients. The ulcer had been present for a
mean of 10.8 months in these patients (Fig, A and B). The ulcer-healing
rate was 60% in the HVWM group (n ¼ 10 limbs) and 20% in the stan-
dard-care group (n ¼ 10 limbs; P < .05). The percentage change in total
surface area after 6 weeks of treatment was 83.2% in the HVWM group
vs 24.7% in the standard-care group (P < .05; Fig, C).
Conclusions: Patients with chronic venous ulcers treated with a prod-
uct that delivers viable mesenchymal stem cells directly to the wound
achieved superior healing rates over standard treatment alone. Larger trials
will be required to conﬁrm these early ﬁndings.
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Mortality Can Be Reduced in Infrainguinal Reconstruction Even With
an Aggressive Open Surgical Approach in the Endovascular Era: The
Beneﬁts of a Standardized Approach and Regionalization of Carey
R. Clement Darling III, Philip S. K. Paty, Sean P. Roddy, Benjamin B.
Chang, Paul B. Kreienberg, Kathleen J. Ozsvath, John B. Taggert, Yaron
Sternbach. Albany Medical College, Albany, NYyNew England Society for Vascular SurgeryObjectives: Distal revascularization has undergone a transformation
during the last 25 years. With the improvement of endovascular technology
and antiplatelet therapy, many have adopted an aggressive endovascular
approach using open reconstruction sparingly, partially because of the
perception of signiﬁcant mortality and morbidity after open procedures.
During the past 5 years, our group has used a balanced standardized
approach to distal revascularization, using primary open reconstruction for
patients with signiﬁcant foot necrosis, deep space infection, and any
adequate venous conduit. We have also developed a comprehensive network
to transfer patients who need complex reconstructions to a tertiary center
for more deﬁnitive care.
Methods: Data were prospectively collected from our vascular regis-
try. Patient demographics, type of procedure, mortality, morbidity, and
limb salvage were recorded. We compared results from 2003 to 2008
(group A) with results from 2008 to 2013 (group B). In 2008, we adopted
a standardized approach in our practice for patients presenting with signif-
icant peripheral vascular disease.
Results: From 2003 to 2008, our group performed 2996 infrain-
guinal reconstructions (2309 open bypass and 687 endovascular).
Operative mortality was 2.84% (3.33% open, 1.16% endovascular).
From 2008 to 2013, 4321 infrainguinal reconstructions were per-
formed (2314 open, 2007 endovascular). Total mortality was 1.25%
(1.94% open, 0.9% endovascular). The differences were statistically sig-
niﬁcant. Limb salvage and major complications were similar and not
signiﬁcant.
Conclusions: Standardization of indications and procedures and
appropriate transfer of complex patients to a dedicated center can reduce
mortality of patients undergoing infrainguinal reconstruction while main-
taining quality outcomes.
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Long-Term Follow-Up After EVAR: A Contemporary Seriesy
Clayton J. Brinster, Matthew R. Cambria, Emel A. Ergul, Mark F. Conrad,
Richard P. Cambria. Massachusetts General Hospital, Boston, Mass
Objectives: This study was designed to examine the long-term out-
comes after endovascular aneurysm repair (EVAR).
Methods: All clinical preoperative, operative, postoperative, and
follow-up data of patients undergoing EVAR between 2008 and 2012
were collected prospectively and examined retrospectively. Presence of
endoleak, need for secondary intervention, and survival were analyzed.
Results: A total of 464 patients underwent EVAR with approved de-
vices. The average age was 78.9 6 8.0 years, and 379 (82%) were men. Ur-
gent or emergency EVAR was performed in 32 patients (7.1%). The 30-day
mortality was 2.4%. During an average follow-up of 45.4 6 19.1 months,
the relative survival was 62% by Kaplan-Meier analysis. Endoleak developed
in 83 patients (18%): 13 type I (3%), 67 type II (14%), and 2 type III (0.4%).
The average time to detection of endoleak was 17 months (range, 3-54
months), and 27 endoleaks (33%) were detected after the ﬁrst postoperative
computed tomography scan. Spontaneous resolution of type II endoleak
was observed in 40 patients (59%). A total of 57 secondary interventions
were required in 44 patients (9.5%). Indications for reintervention included
type I endoleak in 15 (26%), type II endoleak with sac expansion >5 mm in
30 (53%), limb kinking or thrombosis in 10 (18%), and renal artery stenosis
in 2 (3.5%). Initial secondary intervention was successful in 35 patients
(80%). Freedom from reintervention was 95% at 1 year and 90% at 5 years,
and the average time to reintervention was 20.56 8.3 months. Preoperative
sac size, current systemic anticoagulation, and history of smoking, diabetes,
or hyperlipidemia did not predict development of endoleak or need for
reintervention.
Conclusions: Despite overall favorable results in this contemporary
series, the rate of required secondary intervention at an average of nearly
2 years postprocedure is unchanged from previous reports. The range of
time to initial presentation of endoleak underscores the continued need
for long-term clinical and radiologic surveillance.
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